Author: admin

Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 2 Diabetes pipeline constitutes 75+ key companies continuously working towards developing 80+ Type 2 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Type 2 Diabetes Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.

 

The Type 2 Diabetes Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, spanning from pre-clinical development to market availability. It includes a comprehensive overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development aspects such as technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details.

 

Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight

 

Some of the key takeaways from the Type 2 Diabetes Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years.

  • Type 2 Diabetes companies working in the treatment market are Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others, are developing therapies for the Type 2 Diabetes treatment

  • Emerging Type 2 Diabetes therapies in the different phases of clinical trials are- Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years.

  • In May 2026, Novo Nordisk announced that Ozempic® (semaglutide) tablets in 1.5 mg, 4 mg, and 9 mg strengths will become available in the U.S. for adults with type 2 diabetes starting Monday, May 4. Ozempic® is currently the only FDA-approved oral peptide GLP-1 therapy indicated for adults with type 2 diabetes to help improve blood glucose levels alongside diet and exercise, while also lowering the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death in high-risk patients. Oral semaglutide has previously been marketed for type 2 diabetes under the brand name Rybelsus®, which is offered in a different formulation and dosage range.

  • In March 2026, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, making it the first and only once-weekly long-acting basal insulin for adults with type 2 diabetes. The therapy is approved for use alongside diet and exercise to help improve glycemic control. This approval introduces the only once-weekly basal insulin treatment option currently available, highlighting the growing focus on personalized diabetes care and the need for therapies that better align with individual patient lifestyles, routines, and treatment preferences.

  • In April 2025, Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company specializing in the development of novel peptide-based therapies, has announced the enrollment of the first participant in its Phase 2b ZUPREME-2 trial. This study targets individuals with overweight or Type 2 Diabetes and type 2 diabetes, evaluating the efficacy and safety of once-weekly subcutaneous doses of petrelintide, a long-acting amylin analogue, in comparison to a placebo.

  • In February 2025, Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery system, now approved for use in individuals with type 2 diabetes.

  • In February 2025, Sotagliflozin, which has FDA approval for treating type 2 diabetes and kidney disease, has demonstrated a substantial reduction in the risk of heart attack and stroke among high-risk patients, presenting a promising option for cardiovascular protection.

  • In January 2025, The FDA approved a new indication for semaglutide to help lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, as announced by Novo Nordisk.

 

Type 2 Diabetes Overview

Type 2 Diabetes is a chronic metabolic condition where the body becomes resistant to insulin or doesn’t produce enough insulin, leading to high blood sugar levels. It usually develops in adults but is increasingly seen in younger people due to Type 2 Diabetes and sedentary lifestyles. Unlike Type 1 diabetes, it is often linked to lifestyle factors and can sometimes be managed through diet, exercise, oral medications, or insulin. If left uncontrolled, Type 2 diabetes can cause complications like heart disease, kidney problems, nerve damage, and vision issues. Regular monitoring and healthy lifestyle changes are key to management.

 

Discover breakthrough Type 2 Diabetes therapies transforming future metabolic disease treatment. Explore Type 2 Diabetes Clinical Trials

 

Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:

  • Tirzepatide/LY3298176: Eli Lilly and Company

  • Danuglipron: Pfizer

  • RGT001-075: Regor Pharmaceuticals Inc.

  • AZD0186: AstraZeneca

  • ECC5004: Eccogene

  • PF-07081532: Pfizer

  • XW014: Sciwind Biosciences USA Co., Ltd.

  • MN-001: MediciNova

  • SPI-62: Sparrow Pharmaceuticals

  • HTD1801: HighTide Biopharma Pty Ltd

  • Semaglutide: Novo Nordisk A/S

  • BMF-219: Biomea Fusion Inc.

  • ALT-801: Altimmune, Inc.

  • MBL949: Novartis

  • LY3457263: Eli Lilly and Company

  • AMG 133: Amgen

  • DD01: Neuraly, Inc.

  • CT-868: Carmot Therapeutics, Inc.

  • IVA337: Inventiva Pharma

  • INV-202: Inversago Pharma Inc

  • AT-001: Applied Therapeutics, Inc.

 

Type 2 Diabetes Route of Administration

Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

 

Type 2 Diabetes Molecule Type

Type 2 Diabetes Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Type 2 Diabetes Pipeline Therapeutics Assessment

  • Type 2 Diabetes Assessment by Product Type

  • Type 2 Diabetes By Stage and Product Type

  • Type 2 Diabetes Assessment by Route of Administration

  • Type 2 Diabetes By Stage and Route of Administration

  • Type 2 Diabetes Assessment by Molecule Type

  • Type 2 Diabetes by Stage and Molecule Type

 

DelveInsight’s Type 2 Diabetes Report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies

 

Some of the key companies in the Type 2 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 2 Diabetes are – Novo Nordisk, Jiangsu Hengrui Medicine, Melior Pharmaceuticals, Adocia, Pfizer, AgeX Therapeutics, CarmotTherapeutics, Genexine, Inc., OPKO Health, Inc., VitNovo, Inc., Sciwind Biosciences, Caelus Health, SCOHIA PHARMA, Ionis Pharmaceuticals, Eli Lilly and Company, Oramed Pharmaceuticals, AstraZeneca, Aerami Therapeutics, Viking Therapeutics, VTV Therapeutics, AptamiR Therapeutics, Avolynt, Inc., Suzhou Yabao Pharmaceutical, CONJUCHEM, LLC., Hua Medicine, REMD Biotherapeutics, Novmeta Pharma, Afimmune Limited, Xeris Pharmaceuticals, Akros Pharma Inc., and others.

 

Type 2 Diabetes Pipeline Analysis:

The Type 2 Diabetes pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.

  • Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies

 

Type 2 Diabetes Pipeline Market Drivers

  • Increasing prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Type 2 Diabetes Market.

 

Type 2 Diabetes Pipeline Market Barriers

  • However, side-effects associated with the treatment of Type 2 Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Type 2 Diabetes Market growth.

 

Scope of Type 2 Diabetes Pipeline Drug Insight

  • Coverage: Global

  • Key Type 2 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others

  • Key Type 2 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others

  • Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies

  • Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers

 

Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials

 

Table of Contents

1. Type 2 Diabetes Report Introduction

2. Type 2 Diabetes Executive Summary

3. Type 2 Diabetes Overview

4. Type 2 Diabetes- Analytical Perspective In-depth Commercial Assessment

5. Type 2 Diabetes Pipeline Therapeutics

6. Type 2 Diabetes Late Stage Products (Phase II/III)

7. Type 2 Diabetes Mid Stage Products (Phase II)

8. Type 2 Diabetes Early Stage Products (Phase I)

9. Type 2 Diabetes Preclinical Stage Products

10. Type 2 Diabetes Therapeutics Assessment

11. Type 2 Diabetes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Type 2 Diabetes Key Companies

14. Type 2 Diabetes Key Products

15. Type 2 Diabetes Unmet Needs

16 . Type 2 Diabetes Market Drivers and Barriers

17. Type 2 Diabetes Future Perspectives and Conclusion

18. Type 2 Diabetes Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk

Pancreatic Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Dragonfly Therapeutics, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences, Carisma Therap

The Key Pancreatic Cancer Companies in the market include – AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others.

 

The Pancreatic Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.

 

DelveInsight’s “Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Request a sample for the Pancreatic Cancer Market Report:

https://www.delveinsight.com/report-store/pancreatic-cancer-market

 

Some of the key facts of the Pancreatic Cancer Market Report:

  • The Pancreatic Cancer market size was valued approximately and is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In May 2026, An investigational therapy that could provide new hope for patients with pancreatic cancer has received expanded access authorization from the U.S. Food & Drug Administration (FDA), enabling a broader group of patients to access the drug while clinical studies continue. Pancreatic cancer remains among the most aggressive and difficult-to-treat cancers. The therapy, daraxonrasib (formerly known as RMC-6236), is designed to target mutations in the RAS gene family. Among these, KRAS mutations are the most prevalent, driving more than 90% of pancreatic cancer cases. For decades, researchers considered KRAS mutations largely “undruggable” due to the challenges in effectively targeting them with existing treatments, though recent scientific advances have begun to change that outlook.

  • In May 2026, The U.S. Food and Drug Administration (FDA) has authorized Revolution Medicines to move forward with an expanded access program (EAP) for its investigational RAS(ON) inhibitor, daraxonrasib (RMC-6236), in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The program is intended to provide eligible patients who are unable to enroll in clinical trials with access to the therapy. In a separate announcement, Revolution Medicines reported that its Phase III RASolute 302 study evaluating daraxonrasib successfully achieved its primary endpoints. According to the company, patients with previously treated metastatic pancreatic cancer who received daraxonrasib demonstrated a median overall survival of 13.2 months, compared with 6.7 months in patients treated with chemotherapy.

  • In March 2026, Revolution Medicines announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline including daraxonrasib will be featured at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

  • In February 2026, Novocure announced that the U.S. Food and Drug Administration (FDA) approved OPTUNE Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.

  • In January 2026, ChipScreen Biosciences received regulatory approval from China’s National Medical Products Administration (NMPA) to initiate a new clinical trial for chiauranib in pancreatic cancer, marking a key advancement following encouraging earlier data.

  • In January 2026, Novita Pharmaceuticals, Inc., a privately held clinical-stage biopharmaceutical company focused on developing innovative oncology therapies using its proprietary fascin inhibitor platform, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational small-molecule fascin inhibitor NP-G2-044 for the treatment of pancreatic cancer. Pancreatic cancer remains one of the most lethal cancers, with an estimated five-year survival rate of around 12% and very limited effective treatment options, especially for patients with advanced disease.

  • In November 2025, Artios Pharma is advancing a pipeline of oncology therapies, with alnodesertib as its lead candidate, currently under investigation for second-line pancreatic cancer and third-line colorectal cancer. The company announced that it has raised $115 million in a Series D funding round, which will be used to further develop its oncology pipeline. A significant portion of the funds is earmarked for alnodesertib, supporting its ongoing clinical trials in pancreatic and colorectal cancer.

  • In November 2025, Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical firm with an extensive portfolio of drug candidates addressing hard-to-treat cancers and viral infections, announced that it has established a research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC). This collaboration will support investigator-initiated preclinical studies assessing Annamycin for the treatment of pancreatic cancer.

  • In September 2025, Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. (2563.HK), a synthetic biology-focused biopharma company developing innovative oncology therapies, announced that its lead pipeline candidate Utidelone has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pancreatic cancer. This represents the third ODD awarded to Utidelone, following previous FDA designations for breast cancer brain metastases and gastric cancer.

  • In May 2025, UTR Therapeutics Inc. announced the submission of an IND application to the FDA for UTRxM1-18, a novel therapy targeting c-MYC-driven cancers, including triple-negative breast, pancreatic, colorectal, and ovarian cancers. Using its 3’UTR engineering platform, UTRxM1-18 selectively degrades cancer-specific transcripts while sparing healthy cells. In preclinical studies, the therapy demonstrated robust, dose-dependent efficacy across multiple tumor types with no dose-limiting toxicities.

  • In April 2025, Verastem Oncology has received FDA clearance for its IND application for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, and intends to initiate a Phase 1/2a clinical trial by mid-year in patients with advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers.

  • In March 2025, Swedish immunotherapy company Anocca has obtained regulatory approval in four European countries to launch its Phase I/II VIDAR-1 clinical trial, targeting patients with advanced KRAS-positive pancreatic cancer. The study will begin by evaluating ANOC-001, Anocca’s lead candidate, which specifically targets the KRAS G12V mutation, in which glycine at position 12 is substituted with valine.

  • In March 2025, Boan Biotechnology (06955.HK) announced that its targeted CD228 antibody-drug conjugate, BA1302, has been granted orphan drug designation (ODD) by the U.S. FDA for the treatment of squamous non-small cell lung cancer and pancreatic cancer.

  • As per DelveInsight estimates, exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer accounting for more than 90% of total cases.

  • According to DelveInsight’s analysis, the total number of incident cases of pancreatic cancer in the US was approximately ~63,700 in 2025.

  • According to the analysis, in the US, the majority of pancreatic cancer cases in 2025 were diagnosed at a distant stage (50%), followed by regional (37%) and localized stages (13%), highlighting a concerning trend of late-stage detection.

  • DelveInsight estimates that the United States holds the largest market share in 2025 among the 7MM. Chemotherapy regimens remain the dominant standard of care in first-line pancreatic cancer treatment.

  • The total market size of pancreatic cancer is expected to increase in the 7MM during the forecast period driven by ongoing clinical research and better diagnostic tools which might improve the prognosis of the disease.

  • Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others

  • Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others

  • The Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Cancer than females

 

Pancreatic Cancer Overview

Pancreatic cancer is a type of cancer that originates in the tissues of the pancreas, an organ located behind the stomach that plays a key role in digestion and blood sugar regulation. It often develops silently, showing few early symptoms, which makes it difficult to detect until advanced stages. Common signs may include abdominal pain, jaundice, weight loss, and digestive issues. Pancreatic cancer is aggressive, has a high mortality rate, and treatment options include surgery, chemotherapy, radiation therapy, and targeted therapies, depending on the stage and location of the tumor.

 

To Know in detail about the Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Cancer Market Forecast

 

Pancreatic Cancer Epidemiology Segmentation:

The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of Pancreatic Cancer in the 7MM

  • Molecular Alteration-specific Incident Cases of Pancreatic Cancer in the 7MM

  • Stage-specific Incident Cases of Pancreatic Cancer in the 7MM

 

Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights

 

Pancreatic Cancer Therapies and Key Companies

  • LYNPARZA (olaparib): AstraZeneca

  • KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

  • Elraglusib (9 ING 41): Actuate Therapeutics

  • DF 7001: Dragonfly Therapeutics CMG 901 Keymed B

  • TNG260: Tango Therapeutics

  • ATA 3271: Atara Biotherapeutics

  • CMG 901: Keymed Biosciences Co.Ltd

  • CT-0508: Carisma Therapeutics Inc

  • CUE-102: Cue Biopharma

  • BOLD-100: Bold Therapeutics

  • CM24: Purple Biotech Ltd

  • ENB-003: ENB Therapeutics

  • GRT-C903: Gritstone bio

  • AZD0171: AstraZeneca

  • CAN-2409: Candel Therapeutics

  • Mitazalimab: Alligator Bioscience

  • Pamrevlumab: FibroGen

  • NIS793: Novartis AG

  • Masitinib: AB Science

  • Glufosfamide: Eleison Pharmaceuticals

 

To know more about Pancreatic Cancer treatment, visit @ Pancreatic Cancer Medications

 

Pancreatic Cancer Market Drivers

  • Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Pancreatic Cancer

  • Strong pipeline activity

 

Pancreatic Cancer Market Barriers

  • Rising incidence of cancer will provide a larger window of opportunity for new treatments

  • Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity

 

Scope of the Pancreatic Cancer Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others

  • Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others

  • Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies

  • Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and barriers

  • Pancreatic Cancer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, Pancreatic Cancer Market Access and Reimbursement

 

Discover more about therapies set to grab major Pancreatic Cancer market share @ Pancreatic Cancer Treatment Landscape

 

Table of Contents

1. Pancreatic Cancer Market Report Introduction

2. Executive Summary for Pancreatic Cancer

3. SWOT analysis of Pancreatic Cancer

4. Pancreatic Cancer Patient Share (%) Overview at a Glance

5. Pancreatic Cancer Market Overview at a Glance

6. Pancreatic Cancer Disease Background and Overview

7. Pancreatic Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Pancreatic Cancer

9. Pancreatic Cancer Current Treatment and Medical Practices

10. Pancreatic Cancer Unmet Needs

11. Pancreatic Cancer Emerging Therapies

12. Pancreatic Cancer Market Outlook

13. Country-Wise Pancreatic Cancer Market Analysis (2022–2036)

14. Pancreatic Cancer Market Access and Reimbursement of Therapies

15. Pancreatic Cancer Market drivers

16. Pancreatic Cancer Market barriers

17. Pancreatic Cancer Appendix

18. Pancreatic Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Dragonfly Therapeutics, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences, Carisma Therap

Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

 

DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Narcolepsy Market Report:

https://www.delveinsight.com/report-store/narcolepsy-market

 

Some of the key facts of the Narcolepsy Market Report:

  • According to a 2024 analysis, the narcolepsy market across the 7MM was valued at nearly USD 2.5 billion, driven by rising disease awareness, better diagnostic rates, and the growing availability of treatment options.

  • In February 2026, Harmony Biosciences announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for Wakix (pitolisant) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • In January 2026, Alkermes plc announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to alixorexton for the treatment of narcolepsy type 1.

  • In July 2025, Takeda’s oral narcolepsy therapy, oveporexton, successfully achieved both primary and secondary endpoints in two Phase III clinical studies. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials demonstrated positive results across all endpoints in patients with narcolepsy type 1 (NT1) following 12 weeks of treatment.

  • In June 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has unveiled new Phase 4 findings highlighting the effectiveness of Xywav® (a low-sodium oxybate formulation containing calcium, magnesium, potassium, and sodium) in treating individuals with narcolepsy. The results are part of four late-breaking abstracts from Jazz presented as oral sessions at SLEEP 2025, all of which were chosen by the Associated Professional Sleep Societies (APSS) for their scientific significance and innovation. Xywav remains the only FDA-approved low-sodium oxybate therapy for managing cataplexy or excessive daytime sleepiness (EDS) in narcolepsy patients aged 7 and older, as well as for adults with idiopathic hypersomnia. The recommended dosage ranges from 6 to 9 grams per night.

  • In May 2025, Takeda (TSE: 4502/NYSE: TAK) announced that the New England Journal of Medicine has published results from a Phase 2b trial evaluating oveporexton (TAK-861) in individuals with narcolepsy type 1 (NT1). Oveporexton is an investigational oral therapy that selectively targets orexin receptor 2 (OX2R) to restore orexin signaling, which is deficient in NT1. The trial results showed significant improvements in both objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy episodes, and meaningful improvements in overall disease severity and quality of life across all tested doses when compared to placebo after eight weeks of treatment.

  • In May 2025, A recent Phase IIb clinical trial highlighted encouraging results for Takeda’s oral orexin receptor 2 (OX2R)-selective agonist in treating narcolepsy type 1 (NT1). Published in the New England Journal of Medicine, the data indicates that oveporexton (TAK-861) notably reduced disease severity and helped participants achieve wakefulness levels close to normal. Takeda reports that the therapy is intended to target the core issue in NT1—orexin deficiency—in this long-term neurological disorder.

  • According to Narcolepsy Network Organization, narcolepsy is an under diagnosed sleep disorder which is most common among the adults as compared to the pediatrics.

  • Narcolepsy is classified into two types: Type 1 (with cataplexy) and Type 2 (without cataplexy). Orphanet estimates that NT1 affects between 1 in 2,000 and 1 in 5,000 individuals, making it the more commonly recognized form.

  • As per our secondary analysis based on a large representative sample of the US general population, current prevalence of narcolepsy is reported at 37.7/100,000 individuals (12.6/100,000 for NT1, 25.1/100,000 for NT2), and a yearly occurrence of 2.6/100,000.

  • Prevalence of narcolepsy in Europe was nearly 47 patients per 100,000 persons, with a yearly occurrence of 0.64–1.37 per 100,000.

  • As per our secondary analysis, the worldwide prevalence of narcolepsy is approximately 1 in 2,000, while in Japan, it is approximately 37.5 per 100,000 persons. the average age of onset in Japan is 18 years.

  • According to our secondary analysis, the prevalence for NT1 is 14 per 100,000 people and 65.4 per 100,000 people for NT2. The prevalence is highest in the late teens to early twenties with a 50% greater female predominance in the US.

  • Key Narcolepsy Companies: NLS Pharmaceutics, Suven Life SciencesAlkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others

  • Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others

  • The Narcolepsy epidemiology based on gender analyzed that females are more affected with narcolepsy (type1) than males

  • The Narcolepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

 

Narcolepsy Overview

Narcolepsy is a chronic neurological disorder characterized by the brain’s inability to regulate sleep-wake cycles normally. People with narcolepsy experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, regardless of the amount of nighttime sleep. These sudden sleep attacks can occur during any type of activity.

 

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

 

Narcolepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Narcolepsy Epidemiology Segmentation:

The Narcolepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Subtype-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Age-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Treated Cases of Narcolepsy in the 7MM

 

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

 

Narcolepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Narcolepsy Therapies and Key Companies

  • QUILIENCE (mazindol ER): NLS Pharmaceutics

  • Samelisant (SUVN-G3031): Suven Life Sciences

  • NLS-2: NLS Pharmaceutics

  • ALKS 2680: Alkermes, Inc.

  • JZP258 (XYWAV): Jazz Pharmaceuticals

  • TS-091 5mg: Taisho Pharmaceutical

  • JZP-258: Jazz Pharma

  • SUVN-G3031: Suven Life Sciences Limited

  • JNJ-17216498: Alza Corporation, DE, USA

  • Modafinil: Cephalon

  • sodium oxybate: Orphan Medical

  • THN102 300/3: Theranexus

  • Mazindol: NLS Pharmaceutics

  • AXS-12 (Reboxetine): Axsome Therapeutics, Inc

  • TAK-861: Takeda

  • PF-03654746: Pfizer

  • FT218: Avadel

  • BTD-001: Balance Therapeutics

 

Discover more about therapies set to grab major Narcolepsy market share @ Narcolepsy Treatment Market

 

Narcolepsy Market Strengths

  • Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy.

  • The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

 

Narcolepsy Market Opportunities

  • Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy

  • To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

 

Scope of the Narcolepsy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Narcolepsy Companies: NLS Pharmaceutics, Alkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others

  • Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others

  • Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies

  • Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement

 

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Narcolepsy Market Report Introduction

2. Executive Summary for Narcolepsy

3. SWOT analysis of Narcolepsy

4. Narcolepsy Patient Share (%) Overview at a Glance

5. Narcolepsy Market Overview at a Glance

6. Narcolepsy Disease Background and Overview

7. Narcolepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Narcolepsy

9. Narcolepsy Current Treatment and Medical Practices

10. Narcolepsy Unmet Needs

11. Narcolepsy Emerging Therapies

12. Narcolepsy Market Outlook

13. Country-Wise Narcolepsy Market Analysis (2020–2034)

14. Narcolepsy Market Access and Reimbursement of Therapies

15. Narcolepsy Market Drivers

16. Narcolepsy Market Barriers

17. Narcolepsy Appendix

18. Narcolepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

Metastatic HER2-positive Breast Cancer Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Ambrx, Zymeworks, Jazz Pharma, Roche, Criterium, Seagen, Sichuan

The Key Metastatic HER2-positive Breast Cancer Companies in the market include – MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others.

 

DelveInsight’s “Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Metastatic HER2-positive Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2-positive Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Metastatic HER2-positive Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market

 

Some of the key facts of the Metastatic HER2-positive Breast Cancer Market Report:

  • The metastatic HER2-positive breast cancer market size was estimated at nearly USD 2.9 billion in 2025 and is anticipated to expand at a CAGR of approximately 8.3% during the forecast period from 2026 to 2036.

  • In May 2026, The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd; Enhertu) for two new indications in adults with HER2-positive early-stage breast cancer, marking the therapy’s first approvals in the early-stage setting. The first approval covers the use of neoadjuvant T-DXd followed by taxane, trastuzumab, and pertuzumab (THP) for patients with stage II or III HER2-positive (IHC 3+ or ISH+) breast cancer. The second approval authorizes adjuvant T-DXd for adults with HER2-positive (IHC 3+ or ISH+) breast cancer who continue to have residual invasive disease after receiving neoadjuvant trastuzumab-based, with or without pertuzumab, and taxane-based treatment.

  • In December 2025, Following the strong clinical results reported in June by AstraZeneca and Daiichi Sankyo for Enhertu in a combination regimen for a specific type of breast cancer, the therapy has now received FDA approval for that indication. The U.S. regulator has approved Enhertu in combination with Roche’s Perjeta as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, as confirmed by an FDA-approved diagnostic test.

  • In December 2025, The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in combination with pertuzumab (Perjeta) as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, as determined by an FDA-approved diagnostic test. Alongside this approval, the agency also cleared the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the HER2 Dual ISH DNA Probe Cocktail as companion diagnostic tools to help identify patients eligible for this therapy, according to a regulatory news release.

  • In June 2025, AstraZeneca and Daiichi Sankyo reported positive results from the Phase III DESTINY-Breast09 trial (NCT04784715) evaluating Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab as a first-line therapy for HER2-positive metastatic breast cancer. The Enhertu-pertuzumab combination showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard THP regimen (taxane, trastuzumab, and pertuzumab). Full findings from the study were presented at the 2025 ASCO Annual Meeting.

  • In May 2025, Topline findings from the Phase III DESTINY-Breast11 trial (NCT05113251) revealed that Enhertu (trastuzumab deruxtecan; AstraZeneca and Daiichi Sankyo) followed by standard HER2-targeted therapy significantly improved pathologic complete response (pCR) rates compared to standard chemotherapy in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Investigators noted that these results highlight Enhertu’s potential as an alternative to anthracycline-based regimens for high-risk patients.

  • In February 2025, KN026 combined with docetaxel demonstrated an Objective Response Rate (ORR) of 76.4% in HER2-positive breast cancer. The safety profile of KN026 was manageable, with no treatment-related deaths, and it exhibited a potential advantage in terms of reduced cardiac toxicity.

  • According to the estimates, the total incident population of HER2-positive breast cancer in the seven major markets was nearly 104,000 cases in 2025. The cases in the 7MM are expected to increase during the forecast period, i.e., 2025–2036.

  • The metastatic HER2+ breast cases were highest in the treatment eligible pool for HER2+ breast cancer in the US, accounting for ~14,500 cases.

  • According to the estimates, most cases of HER2-positive breast cancer occur in people between 40 and 60 in the United States, accounting for ~52% of total cases in 2025.

  • Among EU4 and the UK, Germany had the maximum total incident cases of HER2-positive breast cancer, with ~10,800 cases in 2025, while Spain accounted for the least number of cases.

  • In Japan, stage-specific cases of HER2-positive breast cancer were highest in Stage II, accounting for ~6,600 cases in 2025.

  • TUKYSA became the first new molecular entity (NME) to undergo review under Project Orbis, an initiative by the FDA Oncology Center of Excellence (OCE). Project Orbis facilitates the simultaneous submission and review of oncology drugs by multiple international regulatory authorities. This streamlined approach enhances access to innovative treatments for patients on a global scale.

  • Since gaining FDA approval in 2020, TUKYSA has been employed alongside trastuzumab and chemotherapy to combat HER2-positive breast cancer following prior treatments in the metastatic setting. KADCYLA, an ADC, utilizes HERCEPTIN as a guide to delivering chemotherapy directly to HER2-expressing cancer cells.

  • While both are HER2-targeted therapies, they face formidable competition from AstraZeneca and Daiichi Sankyo’s ENHERTU, which outperformed KADCYLA in a head-to-head trial. Following this setback, KADCYLA has been focusing on its use in post-surgical early-stage breast cancer and expanding its reach geographically.

  • In 2025, the total market size of HER2+ MBC in first-line was USD 521 million in the US. The highest revenue was captured by Taxane + Trastuzumab + PERJETA (Pertuzumab) ± Hormone therapies accounting for USD 236 million in 2025.

  • Key Metastatic HER2-positive Breast Cancer Companies: MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

  • Key Metastatic HER2-positive Breast Cancer Therapies: MARGENZA (margetuximab-cmkb), KADCYLA (ado-trastuzumab emtansine), ENHERTU (fam-trastuzumab deruxtecan-nxk), ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

  • The Metastatic HER2-positive Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2-positive Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2-positive Breast Cancer market dynamics.

 

Metastatic HER2-positive Breast Cancer Overview

Metastatic HER2-positive breast cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain, and is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer tends to be more aggressive than other types of breast cancer.

 

To Know in detail about the Metastatic HER2-positive Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2-positive Breast Cancer Market Forecast

 

Metastatic HER2-positive Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Metastatic HER2-positive Breast Cancer Epidemiology Segmentation:

The Metastatic HER2-positive Breast Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incidence of Breast Cancer in the 7MM

  • Stage-specific Incidence of HER2-positive Breast Cancer in the 7MM

  • Incidence of HER2-positive Breast Cancer Cases by Hormonal Status in the 7MM

  • Line-wise Treatment-eligible Pool for HER2-positive Breast Cancer in the 7MM

  • Age-specific Incidence of HER2-positive Breast Cancer in the 7MM

  • Incidence of HER2-positive Breast Cancer in the 7MM

 

Download the report to understand which factors are driving Metastatic HER2-positive Breast Cancer epidemiology trends @ Metastatic HER2-positive Breast Cancer Epidemiology Forecast

 

Metastatic HER2-positive Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2-positive Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2-positive Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic HER2-positive Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Metastatic HER2-positive Breast Cancer Therapies and Key Companies

  • MARGENZA (margetuximab-cmkb): MacroGenics and TerSera Therapeutics

  • KADCYLA (ado-trastuzumab emtansine): Roche/Chugai

  • ENHERTU (fam-trastuzumab deruxtecan-nxk): Daiichi Sankyo/AstraZeneca

  • KADCYLA (ado-trastuzumab emtansine): Roche/Chugai

  • HERCEPTIN HYLECTA: Roche

  • TUKYSA: Seagen

  • MARGENZA: MacroGenics

  • ARX788: Ambrx

  • Zanidatamab: Zymeworks/Jazz Pharmaceuticals

  • TAS2940: Taiho Oncology

  • GQ1001: GeneQuantum Healthcare

  • Giredestrant: Roche

  • Alpelisib: Criterium, Inc.

  • Tucatinib: Seagen Inc.

  • BL-M07D1: Sichuan Baili Pharma

  • BI-1607: BioInvent International AB

 

Discover more about therapies set to grab major Metastatic HER2-positive Breast Cancer market share @ Metastatic HER2-positive Breast Cancer Treatment Landscape

 

Metastatic HER2-positive Breast Cancer Market Drivers

  • Strong uptake of Daiichi/Astra’s ENHERTU in second and third-line metastatic patients, owing to the unprecedented PFS any therapy in later lines could have ever achieved.

  • Therapies for treating patients whose disease is resistant or refractory to prior HER2 treatment can potentially change the market dynamics in later-line settings.

 

Metastatic HER2-positive Breast Cancer Market Barriers

  • As the current landscape of HER2+ is already packed with old aged blockbuster therapies, companies such as Ambrx BioPharma are developing novel therapies, aiming to target ENHERTU treated patients

  • Despite the treatment with ADCs, around 20–30% of patients progress within 12 months, so there can be a significant market opportunity for therapies targeting these patients.

 

Scope of the Metastatic HER2-positive Breast Cancer Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Metastatic HER2-positive Breast Cancer Companies: MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

  • Key Metastatic HER2-positive Breast Cancer Therapies: MARGENZA (margetuximab-cmkb), KADCYLA (ado-trastuzumab emtansine), ENHERTU (fam-trastuzumab deruxtecan-nxk), ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

  • Metastatic HER2-positive Breast Cancer Therapeutic Assessment: Metastatic HER2-positive Breast Cancer current marketed and Metastatic HER2-positive Breast Cancer emerging therapies

  • Metastatic HER2-positive Breast Cancer Market Dynamics: Metastatic HER2-positive Breast Cancer market drivers and Metastatic HER2-positive Breast Cancer market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Metastatic HER2-positive Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic HER2-positive Breast Cancer Market Access and Reimbursement

 

To know more about Metastatic HER2-positive Breast Cancer companies working in the treatment market, visit @ Metastatic HER2-positive Breast Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Metastatic HER2-positive Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic HER2-positive Breast Cancer

3. SWOT analysis of Metastatic HER2-positive Breast Cancer

4. Metastatic HER2-positive Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic HER2-positive Breast Cancer Market Overview at a Glance

6. Metastatic HER2-positive Breast Cancer Disease Background and Overview

7. Metastatic HER2-positive Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic HER2-positive Breast Cancer

9. Metastatic HER2-positive Breast Cancer Current Treatment and Medical Practices

10. Metastatic HER2-positive Breast Cancer Unmet Needs

11. Metastatic HER2-positive Breast Cancer Emerging Therapies

12. Metastatic HER2-positive Breast Cancer Market Outlook

13. Country-Wise Metastatic HER2-positive Breast Cancer Market Analysis (2022–2036)

14. Metastatic HER2-positive Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic HER2-positive Breast Cancer Market Drivers

16. Metastatic HER2-positive Breast Cancer Market Barriers

17. Metastatic HER2-positive Breast Cancer Appendix

18. Metastatic HER2-positive Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic HER2-positive Breast Cancer Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Ambrx, Zymeworks, Jazz Pharma, Roche, Criterium, Seagen, Sichuan

NASH Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NASH Pipeline @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Key Takeaways from the NASH Pipeline Report

  • On May 22, 2026- GlaxoSmithKline initiated a study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
  • On May 20, 2026- Inventiva Pharma conducted a Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts – an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives.
  • On May 18, 2026- Akero Therapeutics Inc. announced a phase 3 Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH.
  • On May 18, 2026- Altimmune Inc. announced a phase 2 study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
  • On May 13, 2026- Madrigal Pharmaceuticals Inc. initiated a Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease.
  • On May 08, 2026- Corcept Therapeutics initiated a phase 2b study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant twice a week for 6 weeks of treatment, followed by a dose escalation to 200 mg miricorilant or placebo twice weekly for an additional 18 weeks which resulting in a total treatment duration of 24 weeks, or to placebo for 24 weeks. (Cohort B).
  • DelveInsight’s NASH Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for NASH treatment.
  • The leading NASH Companies such as Novo Nordisk, Haisco Pharmaceutical Group Co., Ltd., Viking Therapeutics, Tasly Biopharmaceuticals Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Sunshine Lake Pharma Co., Ltd, Corcept Therapeutics, J2H Biotech, GlaxoSmithKline, Hinova Pharmaceuticals Inc., Rivus Pharmaceuticals, Inc., Viking Therapeutics, Inc., Sinew Pharma Inc., Guangdong Raynovent Biotech Co., Ltd, Aligos Therapeutics, Inventiva Pharma, HighTide Biopharma Pty Ltd, MediciNova, Hudson Biotech, OrsoBio, Inc., 89bio, Inc., Inipharm Australia Pty Ltd, Changchun Intellicrown Pharmaceutical Co. LTD, Sino Biopharmaceutical Limited, NorthSea Therapeutics B.V. and others.
  • Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.

Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs

Non-Alcoholic Steatohepatitis Overview

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), characterized by the presence of liver inflammation and hepatocyte injury (ballooning) due to fat accumulation. There are four different clinical phases described for NAFLD. Phase 1 is characterized by simple steatosis and is considered harmless. Some patients progress to Phase 2 developing inflammation and ballooning (NASH). Phase 3 is defined by the presence of NASH with persistent inflammation resulting in liver fibrosis (scarring), which is considered the strongest predictor of liver-related events in NASH patients. Over time, this 3rd stage can lead to a more serious condition, such as liver cirrhosis (Phase 4) or even cancer, where a liver transplant is the only therapy option.

NASH Emerging Drugs Profile

  • Efruxifermin: Novo Nordisk

Efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX appears to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipid metabolism. This holistic approach offers the potential to address the complex, multi-system disease state of MASH, including improvements in lipoprotein risk factors linked to cardiovascular disease the leading cause of death in MASH patients. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • HSK-31679: Haisco Pharmaceutical Group Co., Ltd.

HSK31679 is a novel, liver-directed, orally active thyroid hormone receptor-beta agonist designed to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) and liver fibrosis. It shows superior preclinical efficacy in reducing liver fat and inflammation compared to MGL-3196 (Resmetirom) by modulating gut microbial sphingolipids and inducing an anti-inflammatory environment. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • VK2809: Viking Therapeutics

VK2809, is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promise for the treatment of metabolic disorders, including non-alcoholic steatohepatitis (NASH). The compound successfully achieved both the primary and secondary endpoints in a Phase IIb study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.

  • B1344: Tasly Biopharmaceuticals Co., Ltd.

B1344 is a novel, long-acting polyethylene glycolylated (PEGylated) fibroblast growth factor 21 (FGF21) analog developed for treating nonalcoholic steatohepatitis (NASH) and metabolic diseases. B1344 is sufficient to selectively activate signaling from the βKlotho/FGFR1c receptor complex. In cynomolgus monkeys with nonalcoholic fatty liver disease (NAFLD), administration of B1344 via subcutaneous injection for 11 weeks caused a profound reduction of hepatic steatosis, inflammation, and fibrosis, along with amelioration of liver injury and hepatocyte death, as evidenced by liver biopsy specimen and biochemical analysis. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • ACT500: Xiamen Amoytop Biotech Co., Ltd.

ACT500 (formerly known as NM6606) is an investigational drug candidate being developed by Xiamen Amoytop Biotech Co., Ltd. (Amoytop Biotech), undergoing early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetics (PK) for treating metabolic liver diseases. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).

The NASH Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment.
  • NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market

Explore groundbreaking therapies and clinical trials in the NASH Pipeline @ New NASH Treatment Drugs

NASH Companies

Novo Nordisk, Haisco Pharmaceutical Group Co., Ltd., Viking Therapeutics, Tasly Biopharmaceuticals Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Sunshine Lake Pharma Co., Ltd, Corcept Therapeutics, J2H Biotech, GlaxoSmithKline, Hinova Pharmaceuticals Inc., Rivus Pharmaceuticals, Inc., Viking Therapeutics, Inc., Sinew Pharma Inc., Guangdong Raynovent Biotech Co., Ltd, Aligos Therapeutics, Inventiva Pharma, HighTide Biopharma Pty Ltd, MediciNova, Hudson Biotech, OrsoBio, Inc., 89bio, Inc., Inipharm Australia Pty Ltd, Changchun Intellicrown Pharmaceutical Co. LTD, Sino Biopharmaceutical Limited, NorthSea Therapeutics B.V. and others.

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

NASH Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight’s expert analysis @ NASH Market Drivers and Barriers

Scope of the NASH Pipeline Report

  • Coverage- Global
  • NASH Companies- Novo Nordisk, Haisco Pharmaceutical Group Co., Ltd., Viking Therapeutics, Tasly Biopharmaceuticals Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Sunshine Lake Pharma Co., Ltd, Corcept Therapeutics, J2H Biotech, GlaxoSmithKline, Hinova Pharmaceuticals Inc., Rivus Pharmaceuticals, Inc., Viking Therapeutics, Inc., Sinew Pharma Inc., Guangdong Raynovent Biotech Co., Ltd, Aligos Therapeutics, Inventiva Pharma, HighTide Biopharma Pty Ltd, MediciNova, Hudson Biotech, OrsoBio, Inc., 89bio, Inc., Inipharm Australia Pty Ltd, Changchun Intellicrown Pharmaceutical Co. LTD, Sino Biopharmaceutical Limited, NorthSea Therapeutics B.V. and others.
  • NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036, and others.
  • NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NASH Pipeline Therapies and clinical trials @ NASH Companies, Key Products and Unmet Needsa

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Nonalcoholic Steatohepatitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lanifibranor: Inventiva Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TERN-501: Terns Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. LY3849891: Eli Lilly and Company
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Nonalcoholic Steatohepatitis Key Companies
  21. Nonalcoholic Steatohepatitis Key Products
  22. Nonalcoholic Steatohepatitis- Unmet Needs
  23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
  24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
  25. Nonalcoholic Steatohepatitis Analyst Views
  26. Nonalcoholic Steatohepatitis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NASH Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insights 2026” report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Antisense Oligonucleotide Therapeutics pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Antisense Oligonucleotide Therapeutics Pipeline @ https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight

Key Takeaways from the Antisense Oligonucleotide Therapeutics Pipeline Report

  • On May 18, 2026- GlaxoSmithKline initiated a study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks. b) Nucleos (t)ide analogue (NA) treatment for 24 weeks. c) NA cessation stage OR Continue NA for 24 weeks. d) Durability of response and follow up for further 24 weeks for participants who stopped NA treatment at Week 48.
  • DelveInsight’s Antisense Oligonucleotide Therapeutics pipeline report depicts a robust space with 70+ active players working to develop 90+ pipeline therapies for Antisense Oligonucleotide Therapeutics treatment.
  • The leading Antisense Oligonucleotide Therapeutics Companies such as Novartis Pharmaceuticals, GSK, Ionis Pharmaceuticals, Wave Life Sciences, Bio-Path Holdings, Autotelic Bio, NS Pharma, TransCode Therapeutics, Amylyx Pharmaceuticals, Inc. and others.
  • Promising Antisense Oligonucleotide Therapeutics Pipeline Therapies such as VCA-894A, BP1001, GSK3228836, QR-010, Sepofarsen, SB012 and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Antisense Oligonucleotide Therapeutics Treatment Drugs

The Antisense Oligonucleotide Therapeutics Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Antisense Oligonucleotide Therapeutics Pipeline Report also highlights the unmet needs with respect to the Antisense Oligonucleotide Therapeutics.

Antisense Oligonucleotide Therapeutics Overview

Antisense Oligonucleotide (ASO) Therapeutics represent a rapidly advancing class of precision medicines designed to modulate gene expression at the RNA level. These short, synthetic strands of nucleic acids are engineered to bind selectively to target messenger RNA (mRNA), enabling the inhibition, correction, or modification of disease-causing gene products. By acting upstream of protein synthesis, ASO therapeutics offer a highly targeted approach to treating diseases with well-defined genetic or molecular drivers. One of the key strengths of ASO therapeutics lies in their mechanistic versatility. Depending on their design, ASOs can induce RNA degradation via RNase H, alter RNA splicing, block translation, or modulate microRNA activity. This flexibility has positioned ASOs as a promising modality across a wide range of indications, including neurological disorders, rare genetic diseases, cardiovascular conditions, metabolic disorders, and oncology.

Antisense Oligonucleotide Therapeutics Emerging Drugs Profile

  • Pelacarsen: Novartis Pharmaceuticals

Pelacarsen (TQJ230), also known as IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a), or Lp (a) – a very atherogenic and thrombogenic form of LDL. Elevated Lp (a) is recognized as an independent genetic cause of coronary artery disease, heart attack, stroke, and peripheral arterial disease. Pelacarsen, an investigational antisense medicine designed to lower Lp(a), was discovered by Ionis and licensed to Novartis in 2019. Currently the drug is in Phase III for the treatment of Hyperlipoproteinaemia.

  • WVE-N531: Wave Life Sciences

WVE-N531 is an exon skipping oligonucleotide being developed as a disease modifying treatment for boys with Duchenne muscular dystrophy amenable to exon 53 skipping. WVE-N531 was designed using Wave’s best-in-class oligonucleotide chemistry modifications, including PN backbone chemistry. WVE-N531 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food & Drug Administration. Currently the drug is in Phase III for the treatment of Duchenne Muscular Dystrophy.

  • BP1002: Bio-Path Holdings

BP1002 (Liposomal Bcl-2) is a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Bcl-2, a protein involved in blocking programmed cell death. Bcl-2 is overexpressed in a wide variety of tumors, including NHL and chronic lymphocytic leukemia. Overexpression of Bcl-2 stops affected cells from being killed by chemotherapy. We believe that BP1002 will inhibit Bcl-2 protein expression without inherent toxicity. The introduction of a new, non-toxic, and specific Bcl-2 inhibitor could be a major advance in cancer therapeutics. A Phase I clinical trial for BP1002 in patients with relapsed or refractory NHL or chronic lymphocytic leukemia is currently underway.

  • NS-051/NCNP-04: NS Pharma

NS‑051/NCNP‑04 is an antisense oligonucleotide co‑developed by NS Pharma (a subsidiary of Nippon Shinyaku) and Japan’s National Center of Neurology and Psychiatry to treat Duchenne muscular dystrophy by targeting exon 51 of the dystrophin gene. It promotes skipping of exon 51, enabling production of a shorter yet functional dystrophin protein to preserve or improve muscle function in patients with mutations amenable to this approach. The compound is currently in preclinical development and was granted FDA Rare Pediatric Disease. NS‑051/NCNP‑04 exemplifies the company’s strategic focus on exon‑skipping therapies for neuromuscular disorders. The drug is currently in preclinical stage of its development.

The Antisense Oligonucleotide Therapeutics Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Antisense Oligonucleotide Therapeutics with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Antisense Oligonucleotide Therapeutics Treatment.
  • Antisense Oligonucleotide Therapeutics Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Antisense Oligonucleotide Therapeutics Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Antisense Oligonucleotide Therapeutics market

Explore groundbreaking therapies and clinical trials in the Antisense Oligonucleotide Therapeutics Pipeline @ New Antisense Oligonucleotide Therapeutics Drugs

Antisense Oligonucleotide Therapeutics Companies

Novartis Pharmaceuticals, GSK, Ionis Pharmaceuticals, Wave Life Sciences, Bio-Path Holdings, Autotelic Bio, NS Pharma, TransCode Therapeutics, Amylyx Pharmaceuticals, Inc. and others.

Antisense Oligonucleotide Therapeutics pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Antisense Oligonucleotide Therapeutics Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Antisense Oligonucleotide Therapeutics Market Drivers and Barriers

Scope of the Antisense Oligonucleotide Therapeutics Pipeline Report

  • Coverage- Global
  • Antisense Oligonucleotide Therapeutics Companies- Novartis Pharmaceuticals, GSK, Ionis Pharmaceuticals, Wave Life Sciences, Bio-Path Holdings, Autotelic Bio, NS Pharma, TransCode Therapeutics, Amylyx Pharmaceuticals, Inc. and others.
  • Antisense Oligonucleotide Therapeutics Pipeline Therapies- VCA-894A, BP1001, GSK3228836, QR-010, Sepofarsen, SB012 and others.
  • Antisense Oligonucleotide Therapeutics Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Antisense Oligonucleotide Therapeutics Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Antisense Oligonucleotide Therapeutics Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Antisense Oligonucleotide Therapeutics: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Antisense Oligonucleotide Therapeutics– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pelacarsen: Novartis Pharmaceuticals
  9. Mid Stage Products (Phase II)
  10. WVE-N531: Wave Life Sciences
  11. Early Stage Products (Phase I)
  12. BP1002: Bio-Path Holdings
  13. Preclinical Stage Products
  14. NS-051/NCNP-04: NS Pharma
  15. Inactive Products
  16. Antisense Oligonucleotide Therapeutics – Collaborations Assessment- Licensing / Partnering / Funding
  17. Antisense Oligonucleotide Therapeutics – Unmet Needs
  18. Antisense Oligonucleotide Therapeutics – Market Drivers and Barriers
  19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/antisense-oligonucleotide-therapeutics-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Hemophilia Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Hemophilia Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Hemophilia Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight

Key Takeaways from the Hemophilia Pipeline Report

  • On May 19, 2026- Pfizer conducted a study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study will open enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years will be permitted to enroll. Lastly, children aged 1 to 5 years will be permitted to enroll.
  • On May 19, 2026- Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the “study drug”. Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
  • On May 18, 2026- Bayer conducted a phase 1/2 Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A. In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.
  • On May 15, 2026- Sanofi initiated a phase 3 study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to
  • On May 12, 2026- Octapharma initiated a study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment.
  • On May 11, 2026- CSL Behring announced a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
  • DelveInsight’s Hemophilia pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Hemophilia treatment.
  • The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
  • Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.

Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies

Hemophilia Overview

Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. Blood contains many proteins called clotting factors that can help to stop bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the amount of factor in the blood. The lower the amount of the factor, the more likely it is that bleeding will occur which can lead to serious health problems. In rare cases, a person can develop hemophilia later in life. The majority of cases involve middle-aged or elderly people, or young women who have recently given birth or are in the later stages of pregnancy.

Hemophilia Emerging Drugs Profile

  • SerpinPC: Centessa Pharmaceuticals

SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.

  • Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.

  • ASC 618: ASC Therapeutics

ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.

The Hemophilia Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment.
  • Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market.

Get a detailed analysis of the latest innovations in the Hemophilia Pipeline @ Hemophilia Unmet Needs

Hemophilia Companies

Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives

Scope of the Hemophilia Pipeline Report

  • Coverage- Global
  • Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
  • Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
  • Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hemophilia drug development? @ Hemophilia Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Hemophilia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hemophilia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Fitusiran: Alnylam Pharmaceuticals
  9. Mid Stage Products (Phase II)
  10. SerpinPC: Centessa Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. Drug name: Company Name
  14. Preclinical and Discovery Stage Products
  15. Drug name: Company Name
  16. Inactive Products
  17. Hemophilia Key Companies
  18. Hemophilia Key Products
  19. Hemophilia- Unmet Needs
  20. Hemophilia- Market Drivers and Barriers
  21. Hemophilia- Future Perspectives and Conclusion
  22. Hemophilia Analyst Views
  23. Hemophilia Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Pompe Disease Treatment Pipeline Shows Strong Momentum as 15+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Pompe Disease Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the Pompe Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pompe Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Pompe Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight

Key Takeaways from the Pompe Disease Pipeline Report

  • On May 05, 2026- AskBio Inc. initiated a study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD). A study duration will include a screening period of up to 75 days, primary observation of 52 weeks, and a long-term follow-up period of 4 years.
  • DelveInsight’s Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pompe Disease treatment.
  • The leading Pompe Disease Companies such as Asklepios Biopharmaceutical, GeneCradle Therapeutics, Astellas Gene Therapies, Maze Therapeutics, M6P Therapeutics, Entrada Therapeutics and others.
  • Promising Pompe Disease Pipeline Therapies such as ALGLUCOSIDASE ALFA, ACTUS-101, ATB200, AT2221, BMN 701, Duvoglustat, Myozyme, Methotrexate, GC301 and others.

Stay informed about the cutting-edge advancements in Pompe Disease Treatments @ Pompe Disease Clinical Trials Assessment

Pompe Disease Overview

Pompe disease also known as Glycogen Storage Disease Type II belongs to the ‘lysosomal storage disorders’ (LSDs) group of diseases. Within the cells, lysosomes are tiny compartments where all sorts of substances are recycled. By the action of digestive enzymes, the compounds are degraded. There are currently more than 50 different LSDs that are considered to be caused by the deficiency of one of these enzymes. One such enzyme is acid alpha-glucosidase (GAA) and is responsible for glycogen’s lysosomal degradation. Glycogen accumulates inside the lysosomes due to a lack or dysfunction of GAA, which eventually leads to cellular failure, cellular damage, tissue damage, and ultimately organ dysfunction.

Pompe Disease Emerging Drugs Profile

  • GC301: GeneCradle Therapeutics

GC301 injection is an AAV gene therapy drug designed and developed by Genecradle Therapeutics for the treatment of Pompe disease. It adopts a one-time intravenous injection strategy for widespread systemic expression, aiming to directly compensate for the GAA gene deficiency in tissues such as the liver, heart, skeletal muscles, and central nervous system. In previous clinical trials conducted (IIT+IND), IOPD subjects successfully discontinued enzyme replacement therapy after gene therapy, with varying degrees of improvement in motor ability. Currently, the drug is in the Phase I/II stage of its clinical trial for the treatment of Pompe disease.

  • MZE001: Maze Therapeutics

MZE001 is an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup. GYS1 is an enzyme responsible for glycogen production. MZE001 is currently being evaluated as a potential oral treatment for patients with Pompe disease, as well as other glycogen storage disorders. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of Pompe disease.

Pompe Disease Market Drivers

  • Increased Incidence of Pompe Disease
  • Increased Research and Clinical Activities

Pompe Disease Market Barriers

  • Substantial costs associated with the treatment
  • Late Pompe Disease Diagnosis

Get a detailed analysis of the latest innovations in the Pompe Disease pipeline @ Pompe Disease Unmet Needs

Pompe Disease Companies

Asklepios Biopharmaceutical, GeneCradle Therapeutics, Astellas Gene Therapies, Maze Therapeutics, M6P Therapeutics, Entrada Therapeutics and others.

The Pompe Disease Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.
  • Pompe Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Pompe Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Stay informed about how we’re transforming the future of genetic disorders @ Pompe Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Pompe Disease Pipeline Report

  • Coverage- Global
  • Pompe Disease Companies- Asklepios Biopharmaceutical, GeneCradle Therapeutics, Astellas Gene Therapies, Maze Therapeutics, M6P Therapeutics, Entrada Therapeutics and others.
  • Pompe Disease Pipeline Therapies- ALGLUCOSIDASE ALFA, ACTUS-101, ATB200, AT2221, BMN 701, Duvoglustat, Myozyme, Methotrexate, GC301 and others.
  • Pompe Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pompe Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Pompe Disease Pipeline on our website @ Pompe Disease Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Pompe Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pompe Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Mid-Stage Products (Phase II)
  10. Drug name: Company name
  11. Early Stage Products (Phase I)
  12. MZE001: Maze Therapeutics
  13. Preclinical and Discovery Stage Products
  14. ERT/Oligonucleotide: Entrada Therapeutics
  15. Inactive Products
  16. Pompe Disease Companies
  17. Pompe Disease Products
  18. Pompe Disease Unmet Needs
  19. Pompe Disease Market Drivers and Barriers
  20. Pompe Disease Future Perspectives and Conclusion
  21. Pompe Disease Analyst Views
  22. Pompe Disease Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pompe Disease Treatment Pipeline Shows Strong Momentum as 15+ Pharma Companies in the Race | DelveInsight

Prostate Cancer Clinical Trial Pipeline Expands as 140+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Prostate Cancer Pipeline Insight 2026” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Prostate Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight

Key Takeaways from the Prostate Cancer Pipeline Report

  • On May 15, 2026- Merck Sharp & Dohme LLC conducted a phase 1/2 substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
  • On May 11, 2026- Aragon Pharmaceuticals Inc. initiated a Phase 3 clinical trial is an essential step in the evaluation of an investigational medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN study is to compare the safety and effectiveness of the investigational medication to placebo in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill that looks like the investigational medication but does not contain any active medication, a dummy pill.
  • On May 11, 2026- Janssen Research & Development LLC announced a phase IV study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
  • DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Prostate Cancer treatment.
  • The leading Prostate Cancer Companies such as Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd and others.
  • Promising Prostate Cancer Pipeline such as Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.

Get insights into Prostate Cancer Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Prostate Cancer Treatment Drugs

Prostate Cancer Overview

Prostate Cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. Prostate cancer is mainly caused due to the changes in the DNA. These changes occur because of mutation in DNA. Prostate cancer is diagnosed when the cancer stage advances and symptoms are visible. However early screening test can be performed to find cancer in people before they show any symptoms.

Prostate Cancer Emerging Drugs

  • Niraparib: Janssen Research & Development

Niraparib is an orally administered selective poly ADP-ribose polymerase (PARP) inhibitor. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO for exclusive rights to niraparib in prostate cancer. In the US, niraparib is indicated for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK. The drug is currently being evaluated in Phase III clinical trials to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mCSPC).

  • ZEN 3694: Zenith Epigenetics

ZEN-3694 is an orally bioavailable, potent, small molecule BET inhibitor that selectively binds to both bromodomains of the BET proteins. The drug candidate was discovered and developed from a BET bromodomain inhibitor platform. Bromodomain and Extra-Terminal domain (BET) family of proteins (BRD2, BRD3, BRD4, and BRDT) can bind acetylated lysines through their tandem bromodomains to promote gene transcription. BET bromodomain inhibitors (BETi) target super enhancers and inhibit several programs involved in tumorigenesis such as proliferation, metastasis, invasion, and immune evasion. The drug is currently being evaluated in the Phase II stage of its development for the treatment of Prostate cancer.

  • Ladiratuzumab vedotin: Seagen

Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics’ proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death. Currently, the drug is in the Phase II stage of its development for the treatment of Prostate Cancer.

  • FOR46: Fortis Therapeutics

FOR46 is a fully human antibody conjugated to a potent payload, depending on the indication. Fortis Therapeutics is developing FOR46, a novel antibody-drug conjugate (ADC) against CD46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The Company is also evaluating additional indications for FOR46. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.

  • REGN5678: Regeneron Pharmaceuticals

REGN5678 is designed to bind to CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA on tumor cells. By binding to the costimulatory T-cell-specific surface glycoprotein and tumor-associated antigen, the drug candidate could activate CTLs and direct them to attack cancer cells. Regeneron identified the targeting of CD28 on previously activated T cells as a way to reduce toxicity compared to CD3 bispecifics. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.

The Prostate Cancer Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer treatment.
  • Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.

Explore groundbreaking therapies and clinical trials in the Prostate Cancer Pipeline @ New Prostate Cancer Drugs

Prostate Cancer Companies

Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd and others.

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

Prostate Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Learn about new drugs, pipeline developments @ Prostate Cancer Market Drivers and Barriers

Scope of the Prostate Cancer Pipeline Report

  • Coverage- Global
  • Prostate Cancer Companies- Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd and others.
  • Prostate Cancer Pipeline- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
  • Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Prostate Cancer drug development? @ Prostate Cancer Emerging Drugs and Major Companies

Table of contents

  1. Introduction
  2. Executive Summary
  3. Prostate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Prostate Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Niraparib: Janssen Research & Development
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ZEN 3694: Zenith Epigenetics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. FOR46: Fortis Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Product Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Prostate Cancer Key Companies
  21. Prostate Cancer Key Products
  22. Prostate Cancer- Unmet Needs
  23. Prostate Cancer- Market Drivers and Barriers
  24. Prostate Cancer- Future Perspectives and Conclusion
  25. Prostate Cancer Analyst Views
  26. Prostate Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Clinical Trial Pipeline Expands as 140+ Companies Driving Innovation in the Therapeutics | DelveInsight

Retinitis Pigmentosa Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Retinitis Pigmentosa Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in the Retinitis Pigmentosa pipeline landscape. It covers the Retinitis Pigmentosa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinitis Pigmentosa Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Retinitis Pigmentosa Pipeline? Click here to explore the therapies and trials making headlines @ Retinitis Pigmentosa Pipeline Outlook Report

Key Takeaways from the Retinitis Pigmentosa Pipeline Report

  • On May 19, 2026, Octant Inc. initiated the phase 1a study will be a single dose, double-masked, placebo-controlled ascending dose escalation (SAD +/- food effect) to evaluate the safety, tolerability, and PK of OCT-980 in healthy volunteers. The phase 1b/2 study will be open-label, multi-center multiple ascending dose escalation (MAD) to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of multiple-ascending doses of OCT-980 for up to 48 weeks, in participants with a genetic diagnosis of Rhodopsin-associated, autosomal dominant Retinitis Pigmentosa (RP).
  • On May 15, 2026, SparingVision conducted a Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).
  • On May 08, 2026, Janssen Research & Development LLC announced a phase 2 study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
  • DelveInsight’s Retinitis Pigmentosa Pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Retinitis Pigmentosa treatment.
  • The leading Retinitis Pigmentosa Companies such as Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye and others.
  • Promising Retinitis Pigmentosa Therapies such as Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.

Want to know which companies are leading innovation in Retinitis Pigmentosa? Dive into the full pipeline insights @ Retinitis Pigmentosa Clinical Trials Assessment

The Retinitis Pigmentosa Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Retinitis Pigmentosa Pipeline Report also highlights the unmet needs with respect to the Retinitis Pigmentosa.

Retinitis Pigmentosa Overview

Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa.

Retinitis Pigmentosa Emerging Drugs Profile

  • BIIB-112: Biogen

BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.

  • QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.

If you’re tracking ongoing Retinitis Pigmentosa Clinical trials, this press release is a must-read @ Retinitis Pigmentosa Treatment Drugs

The Retinitis Pigmentosa Pipeline report provides insights into:-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Retinitis Pigmentosa with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa Treatment.
  • Retinitis Pigmentosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Retinitis Pigmentosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinitis Pigmentosa market.

Retinitis Pigmentosa Companies

Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye and others.

Retinitis Pigmentosa Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Retinitis Pigmentosa Products have been categorized under various Molecule types such as,

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

From emerging drug candidates to competitive intelligence, the Retinitis Pigmentosa Pipeline Report covers it all – check it out now @ Retinitis Pigmentosa Market Drivers and Barriers, and Future Perspectives

Scope of the Retinitis Pigmentosa Pipeline Report

  • Coverage- Global
  • Retinitis Pigmentosa Companies- Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye and others.
  • Promising Retinitis Pigmentosa Therapies such as Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.
  • Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Retinitis Pigmentosa Treatment landscape in this detailed analysis @ Retinitis Pigmentosa Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Retinitis Pigmentosa: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Retinitis Pigmentosa Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug name: Company name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. BIIB-112: Biogen
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. N-acetylcysteine-amide: Nacuity Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. SPVN 06: SparingVision
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Retinitis Pigmentosa Key Companies
  23. Retinitis Pigmentosa Key Products
  24. Retinitis Pigmentosa- Unmet Needs
  25. Retinitis Pigmentosa- Market Drivers and Barriers
  26. Retinitis Pigmentosa- Future Perspectives and Conclusion
  27. Retinitis Pigmentosa Analyst Views
  28. Retinitis Pigmentosa Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinitis-pigmentosa-retinitis-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinitis Pigmentosa Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight